SureTrader SureTrader
Home > Boards > US Listed > Medical - Drugs >

Imprimis Pharmaceuticals Inc (IMMY)

IMMY RSS Feed
Add IMMY Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board:
Last Post: 4/5/2016 1:21:41 AM - Followers: 61 - Board type: Free - Posts Today: 0
Imprimis Pharmaceuticals, Inc.
 
NASDAQ
: IMMY

Oct 22, 2015. Last month, Turing Pharmaceuticals LLC, the sole supplier of Daraprim, increased the price of this prescription drug from $13.50 per tablet to a reported $750.00 per tablet. The FDA-approved label for Daraprim indicates that it is prescribed for toxoplasmosis and other types of infections. Toxoplasmosis can be of major concern for patients with weakened immune systems such as patients with HIV/AIDS, pregnant women and children. According to the Centers for Disease Control and Prevention, pyrimethamine works to block folic acid synthesis in the parasite T. gondii, the cause of toxoplasmosis, and leucovorin helps to reverse the negative effects on bone marrow caused by this mechanism of action.

Imprimis is now offering customizable compounded formulations of pyrimethamine and leucovorin in oral capsules starting as low as $99.00 for a 100 count bottle, or at a cost of under a dollar per capsule. Compounded medications may be appropriate for prescription when a commercially-available medicine does not meet the specific needs of a patient. For ordering information, please visit www.imprimiscares.com.

Mark L. Baum, CEO of Imprimis stated, "It is indisputable that generic drug prices have soared recently. While we have seen an increase in costs associated with regulatory compliance, recent generic drug price increases have made us concerned and caused us to take positive action to address an opportunity to help a needy patient population. While we respect Turing's right to charge patients and insurance companies whatever it believes is appropriate, there may be more cost-effective compounded options for medications, such as Daraprim, for patients, physicians, insurance companies and pharmacy benefit managers to consider. This is not the first time a sole supply generic drug – especially one that has been approved for use as long as Daraprim – has had its price increased suddenly and to a level that may make it unaffordable. In response to this recent case and others that we will soon identify, Imprimis is forming a new program called Imprimis Cares which is aligned to our corporate mission of making novel and customizable medicines available to physicians and patients today at accessible prices."

Mr. Baum added, "Today, some drug prices are simply out of control and we believe we may be able to help control costs by offering compounded alternatives to several sole source legacy generic drugs. Imprimis Cares and its team of compounding pharmacists will work with physicians and their patients to ensure they have affordable access to the medicines they need from the over 7,800 generic FDA-approved drugs. Imprimis Cares, available in all 50 states, will work with all third party insurers, pharmacy benefit managers and buying groups to offer its patient specific customizable compounded drug formulations at prices that ensure accessibility and that provide a reasonable profit for Imprimis. We are here to serve our patients and their physicians. We believe that when we do a great job serving our customers, our shareholders will also benefit."

Imprimis' finished compounded drug formulations do not have an FDA-approval label for recommended use. Imprimis compounded formulations are not FDA approved and may only be prescribed pursuant to a physician prescription for an individually identified patient consistent with federal and state laws governing compounded drug formulations.

Daraprim® is a registered trademark of Turing Pharmaceuticals LLC. Imprimis is not affiliated with Turing Pharmaceuticals LLC nor Daraprim®. Daraprim® is an FDA-approved drug. Please consult with your physician regarding which prescription options are most suitable for your specific needs.

ABOUT IMPRIMIS PHARMACEUTICALS

San Diego-based Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) is a national leader in the development, production and dispensing of novel compounded pharmaceuticals. The company's business primarily consists of four therapeutic segments including ophthalmology, urology, sinus and integrative medicine. Imprimis dispenses compounded pharmaceuticals in all 50 states from four facilities located in California, Texas, New Jersey and Pennsylvania. For more information about Imprimis, please visit the corporate website at www.ImprimisPharma.com.




http://www.imprimispharma.com/


 
Common stock outstanding after the offering       8,391,172

Cash and cash equivalents                                            18,059,285
 
   
   
 

MORE INFORMATION WILL BE ADDED TO THIS INTRO MESSAGE WHEN MADE AVAILABLE. THANKS FOR YOUR PATIENCE.

 
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
IMMY
Current Price
Volume:
Bid Ask Day's Range
SureTrader
PostSubject
#3123   Any idea what these guys are doing now? BrazenBull 04/05/16 01:21:41 AM
#3122   Back in at 3.81 MasterBidder 02/12/16 01:36:06 PM
#3121   Sure did. trickledownfacists 12/17/15 05:36:13 PM
#3120   That Martin clown that jacked price on the MasterBidder 12/17/15 03:02:31 PM
#3119   http://www.biopharmadive.com/news/senators-mull-speedier-generics-pathway-amid-o ronk 12/10/15 11:57:39 AM
#3118   He just doesn't get it. Karma is gonna ronk 12/06/15 01:19:54 PM
#3117   Hey SG.. ronk 12/04/15 07:29:53 PM
#3116   So Imprimis used to be transdel pharmaceuticals... Was this Stock Guy777 12/04/15 06:57:48 PM
#3115   SA article from yesterday: ronk 12/03/15 09:52:51 AM
#3114   The Express Scripts news is really interesting. Back ronk 12/01/15 06:43:43 PM
#3113   Up big pm MasterBidder 12/01/15 09:15:11 AM
#3112   Great news! ronk 12/01/15 08:46:23 AM
#3111   Express Scripts Champions $1 per Pill Access to trickledownfacists 12/01/15 12:36:12 AM
#3110   6.66 maybe [SMART MONEY] 11/30/15 03:29:23 PM
#3109   Pricing come out? MasterBidder 11/30/15 03:11:55 PM
#3108   Nice start MasterBidder 11/30/15 09:34:44 AM
#3107   People want in. I bet we gap up Monday. Westorious 11/27/15 04:03:40 PM
#3106   That day it hit a low of 5. ronk 11/27/15 03:06:51 PM
#3105   Trade at 8.00 ah MasterBidder 11/27/15 02:34:18 PM
#3104   Yep :) MasterBidder 11/27/15 02:20:37 PM
#3103   Imagine if 5-10M volume comes in here [SMART MONEY] 11/27/15 02:11:22 PM
#3102   The dd is good on this one and MasterBidder 11/27/15 01:52:26 PM
#3101   NVISION Eye Centers Sign National Account Agreement for [SMART MONEY] 11/27/15 01:47:10 PM
#3100   Imprimis' Fight Against Martin Shkreli Is Part Of [SMART MONEY] 11/27/15 01:45:47 PM
#3099   Seriously. This new Turing pharm news is definitely helping. Westorious 11/27/15 01:41:30 PM
#3098   Thought it was only a matter of time ronk 11/27/15 01:17:09 PM
#3097   Big day MasterBidder 11/27/15 12:48:54 PM
#3096   I'll add through January. 503b in Feb. ronk 11/27/15 12:05:34 AM
#3095   I'm buying more shares tomorrow! Westorious 11/26/15 11:08:30 PM
#3094   Great piece about the trending compounding pharma industry: ronk 11/26/15 10:07:04 PM
#3093   Happy holiday, Westo! ronk 11/26/15 07:31:13 PM
#3092   That's a company I want to invest in. Westorious 11/26/15 07:16:23 PM
#3091   Thought the same. Imagine a company like IMMY ronk 11/26/15 07:00:42 PM
#3090   Good for us! Westorious 11/26/15 06:36:29 PM
#3089   Of course he breaks his promise for a ronk 11/26/15 10:23:10 AM
#3088   Thanks ronk Stock Guy777 11/25/15 10:04:55 AM
#3087   This is a recent corporate presentation with a ronk 11/24/15 05:43:21 PM
#3086   Do you happen to know an accurate authorized Stock Guy777 11/24/15 05:07:42 PM
#3085   Absolutely. Been reading up a lot on this Stock Guy777 11/24/15 04:47:24 PM
#3084   I just realized it was a press release ronk 11/24/15 04:37:50 PM
#3083   It's under the news tab . Stock Guy777 11/24/15 04:33:08 PM
#3082   Nice find! Thank you! ronk 11/24/15 03:17:32 PM
#3081   Good news received today: Wangenstein 11/24/15 10:47:35 AM
#3080   Supply back up! MasterBidder 11/23/15 02:52:26 PM
#3079   Of course. Econ 101! Westorious 11/22/15 05:19:02 PM
#3078   Demand became higher than supply MasterBidder 11/21/15 10:19:17 AM
#3077   Great read and analysis Ronk. Always a pleasure. Westorious 11/21/15 01:33:21 AM
#3076   Correction: 503B should be completed by February. I ronk 11/20/15 06:55:00 PM
#3075   Hard to say, Westo. ronk 11/20/15 06:15:58 PM
#3074   Huge day for IMMY. What happened? Westorious 11/20/15 03:50:50 PM
PostSubject